Compare AbbVie Inc (ABBV) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Vanguard International High Dividend Yield ETF — how do they compare? AbbVie Inc trades at $247.77 (market cap $441.94B), while Vanguard International High Dividend Yield ETF trades at $104.49. The key difference: AbbVie Inc pays a 2.77% dividend while Vanguard International High Dividend Yield ETF pays none, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.
| ABBV | VYMI | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $263.58 | $105.05 |
52-Week Low | $197.38 | $82.92 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
VYMI trades at $104.69, up 0.1% on the day, with strong technical momentum as it approaches resistance at $105. The ETF has gained attention for its international dividend strategy, offering a 3.4% yield and delivering 55% total returns since previous coverage. Recent institutional buying and positive media sentiment highlight growing investor interest in international high-yield exposure.
The outlook remains positive given Vanguard's projection of international developed-market stocks outperforming US markets over the next decade. Key opportunities include diversification benefits and strong dividend growth, while risks center on currency fluctuations and global economic volatility. The ETF's technical strength and fundamental appeal support a constructive view for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
